This presents the intriguing prospect that metastatic bone disease could in fact be treated as an osteocyte ciliopathy, with the potential to inhibit development and growth of metastatic lesions, and associated deterioration of bone tissue, via drugs that increase osteocyte primary cilia expression, such as fenoldopam.[57, 58, 59] Further research is required to solidify this link, as the effect resulting from TGF‐β may be associative rather than causative, but these findings present a promising new therapeutic target for metastatic bone disease. This evidence concerns the gene TGFB1 and ciliopathy.